Biocept has developed a patented liquid biopsy technology called Target Selector
that detects cancer biomarkers
Biocept announces the publication of a peer-reviewed article featuring a case series of three patients indicating the clinical utility of Biocept's Target Selector
circulating tumor DNA, or ctDNA, testing in the management of patients with advanced non-small cell lung cancer, or NSCLC.
6404118, provides intellectual property protection for the company's Switch-Blocker technology which is core to its Target Selector
assays for analysis using real-time PCR, Sanger sequencing and next-generation sequencing.
This is the third issued patent for Biocept's Target Selector
assays for molecular analysis using real-time PCR, Sanger sequencing, and next-generation sequencing.
The targets are controlled by a computer called "Bird Brain" which is very appropriate for the wacky target selector
These studies will use Biocept's Target Selector
liquid biopsy assays to detect circulating tumor cells and circulating tumor DNA and compare results with findings from CT or PET scans.
Pursuant to the agreement, the partners plan to evaluate the feasibility of developing best-in-class products based on the integration of Biocept's Target Selector
technology with Thermo Fisher's Ion Torrent NGS platform and Oncomine liquid biopsy-based NGS panels.
Biocept (BIOC), up 18% after announcing a provider agreement with Alliance Global FZ to market and distribute Biocept's Target Selector
liquid biopsy tests in the United Arab Emirates and several other countries...
M2 PHARMA-February 8, 2018-Europe, Japan, and Hong Kong Issue Patents to Biocept for Target Selector